In a strong precursor to its public offering, Rubicon Research has garnered ₹619.08 crore from 32 anchor investors at an allotment price of ₹485 per share.  This move came a day before the IPO opened for retail investors.

IPO Structure & Use of Proceeds

The total IPO size is ₹1,377.5 crore, structured as a fresh issue of ₹500 crore and an Offer For Sale (OFS) of ₹877.5 crore by promoter General Atlantic Singapore RR.

Post-IPO, General Atlantic’s shareholding is expected to fall to just over 35 percent.

Of the ₹619 crore, approximately 49.56 lakh shares (≈ 38.8 % of anchor allocation) went to eight domestic mutual funds.

Prominent anchor investors include Goldman Sachs, HDFC Mutual Fund, Fidelity, Kotak, ICICI Prudential, Amansa Holdings, Aranda Investments, and others.

Strategic Rationale & Outlook

Rubicon Research is a pharmaceutical formulations company with a strong R&D and innovation focus, particularly in specialty and drug-device combination products, geared toward regulated markets like the U.S. Its manufacturing and R&D assets include US FDA-inspected facilities, Health Canada / WHO GMP certified plants, and recent acquisition of Alkem’s Pithampur facility.

The fresh capital is earmarked for debt repayment, inorganic growth (acquisitions / expansion), and general corporate purposes.

On day two of the IPO, the issue saw healthy subscription metrics  by midday, the IPO was ~84 % subscribed, with strong participation from retail investors (2.48×), non-institutional investors, and a respectable showing from Qualified Institutional Buyers.

However, analysts note potential valuation pressures: at the higher end of price band (₹485), the stock may trade at ~55× PE, which some see as aggressive relative to industry peers.